Tempest Therapeutics, Inc. (TPST) AI Stock Analysis
TPST AI stock analysis summary
AI ResearchTempest Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing small molecule cancer therapies. The company generated $0 in trailing twelve months revenue and had an enterprise value of $22.0M. As of June 30, 2026, it held $779,000 in cash against $7.6M in total debt.
- Market cap
- $10.5M
- Revenue (TTM)
- $0
- P/E
- —
- 1Y return
- -94.4% S&P 500 16.8%
- Avg. target
- $7.00 1021.8% vs last close
Bull case
- Wall Street coverage shows 1 Strong Buy rating with a mean price target of $7.00, implying a 1021.8% premium over the last close of $0.62.
- Consensus estimates anticipate EPS to improve 55.0% to -$2.85 for the fiscal year ending December 31, 2026, followed by a 68.4% improvement to -$0.90 the next fiscal year.
- Insiders hold a 30.1% ownership stake in the company, aligning leadership interests with common shareholders.
Bear case
- The stock has dropped 94.4% over the past year and trades at its 52-week low of $0.62.
- Liquidity is constrained with cash and short-term investments of $779,000 against $7.6M in total debt and a current ratio of 0.38 as of June 30, 2026.
- The company generated $0 in revenue over the trailing twelve months and has negative shareholders' equity of -$1.1M.
What Tempest Therapeutics does
Tempest Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics to treat cancer. Its two primary clinical programs include TPST-1495, a dual antagonist targeting EP2 and EP4 receptors of prostaglandin E2, and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha, both undergoing Phase 1 trials for solid tumors. In addition, the company is advancing TREX-1, a cellular enzyme involved in regulating innate immune responses within tumors. Headquartered in South San Francisco, California, the company develops precision medicine approaches to target critical pathways in cancer progression.
Growth and profitability
Annual revenue moved from $277,000 in FY2015 to $653,000 in FY2016, an increase of 135.7%, before falling 54.8% to $295,000 in FY2017, representing a 2-year revenue CAGR of 3.2%. Net losses expanded across this period from -$73.2M in FY2015 to -$82.3M in FY2016 and -$84.6M in FY2017, with net margin reaching -28670.5% in FY2017. For the trailing twelve months ending June 30, 2026, revenue stood at $0, with an operating margin of 0.0%, a profit margin of 0.0%, and diluted earnings per share of -$3.93.
Balance sheet and cash flow
As of June 30, 2026, Tempest Therapeutics held $779,000 in cash and short-term investments alongside total debt of $7.6M, resulting in net debt of $6.8M. Total assets were $9.6M and the current ratio stood at 0.38, while shareholders' equity was -$1.1M, reflecting negative equity. Operating cash flow in FY2017 was -$20.3M and free cash flow was -$20.3M. The company's share count increased 126.6% over a 5-year period as of FY2025.
Valuation and performance
Tempest Therapeutics closed at $0.62 on October 16, 2026, giving it a market cap of $10.5M and an enterprise value of $22.0M. The stock trades at an EV to EBITDA ratio of 0.3x, compared to the median of 12.0x for its US-listed Healthcare peers, and a price-to-book ratio of 22.9x. Over the past year, the shares fell 94.4%, underperforming the S&P 500 ETF (SPY), which generated a return of 16.8%. The stock also trades 61.4% below its 200-day moving average.
What analysts expect
Wall Street coverage includes 1 Strong Buy rating, 0 Buy ratings, and 0 Hold or Sell ratings. The mean price target is $7.00, representing a 1021.8% premium over the last close of $0.62. For the fiscal year ending December 31, 2026, consensus estimates project EPS of -$2.85 and revenue of $0. For the following fiscal year, 1 analyst projects EPS of -$0.90 on $0 in revenue. Tempest Therapeutics has beaten EPS estimates in 1 of the last 4 quarters, with its next earnings date scheduled for November 4, 2026.
Key risks and what to watch
- A current ratio of 0.38 and cash holdings of $779,000 highlight near-term liquidity pressure.
- Shareholder dilution has expanded significantly, reflecting a 126.6% increase in share count over 5 years as of FY2025.
- Stock price volatility is elevated, shown by a beta of -1.71 and a 78.3% decline year-to-date.
- Analysts project revenue to remain at $0 through both the current and next fiscal years.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this TPST AI stock analysis
This page is an AI-written research summary of Tempest Therapeutics, Inc. (TPST). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: TPST income statement, TPST balance sheet, TPST key metrics, TPST analyst forecast, TPST chart. See the TPST stock overview for the latest quote and news.
TPST AI stock analysis FAQ
What is Tempest Therapeutics' revenue?
Over the trailing twelve months ending June 30, 2026, Tempest Therapeutics reported $0 in revenue. Analysts forecast revenue to remain at $0 for both the current and next fiscal years.
When is Tempest Therapeutics' next earnings date?
The company is scheduled to report earnings on November 4, 2026.
Does Tempest Therapeutics pay a dividend?
Tempest Therapeutics does not pay a dividend.
What is the analyst price target for TPST stock?
The mean analyst price target is $7.00, which sits 1021.8% above its last close of $0.62.
How much cash and debt does Tempest Therapeutics hold?
As of June 30, 2026, the company held $779,000 in cash and short-term investments against $7.6M in total debt, resulting in net debt of $6.8M.